ACAT inhibitor (IC50 = 3.3 μM). Inhibits cholesterol esterification and reduces plasma cholesterol levels in rats. Also inhibits tumor growth and prolongs survival time in a melanoma mouse model and reduces tumor growth and metastasis in a pancreatic cancer mouse model.
Sold for research purposes under agreement from Pfizer Inc.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 501.72. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.99 mL||9.97 mL||19.93 mL|
|5 mM||0.4 mL||1.99 mL||3.99 mL|
|10 mM||0.2 mL||1 mL||1.99 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
References are publications that support the biological activity of the product.
Lee et al (1996) Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J.Med.Chem. 39 5031 PMID: 8978833
Yang et al (2016) Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature 531 651 PMID: 26982734
Li et al (2016) Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer. Oncogene 35 6378 PMID: 27132508
If you know of a relevant reference for Avasimibe, please let us know.
View Related Products by Product Action
Keywords: Avasimibe, Avasimibe supplier, CI-1011, ACAT, inhibits, inhibitors, acyl-CoA:cholesterol, O-acyl, transferase, antitumor, Acyl-CoAcholesterol, acyltransferase, Acyl-CoA:Cholesterol, Acyltransferase, 6505, Tocris Bioscience
Citations for Avasimibe
Citations are publications that use Tocris products.
Currently there are no citations for Avasimibe. Do you know of a great paper that uses Avasimibe from Tocris? Please let us know.
Reviews for Avasimibe
There are currently no reviews for this product. Be the first to review Avasimibe and earn rewards!
Have you used Avasimibe?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.